Funding This work is funded by the Deutsche Forschungsgemeinschaft (DFG), RTG 2467, project no
Heres what you need to know: Target Tissue: Works specifically on adipose tissue without systemic growth hormone effects or muscle tissue impact Mechanism: Activates beta-3 adrenergic receptors on fat cell membranes, triggering intracellular fat-burning cascades Primary Action: Stimulates hormone-sensitive lipase to break down stored triglycerides into free fatty acids for energy utilization Secondary Action: Inhibits lipogenic enzymes that convert excess calories into stored fat Regional Selectivity: Particularly effective on visceral (deep abdominal) and subcutaneous fat deposits with high beta-3 receptor concentration Preservation Effect: Targets fat tissue selectively without promoting muscle protein breakdown or affecting lean tissue Unique Advantage: Does not bind to growth hormone receptors, avoiding effects on IGF-1, glucose metabolism, or insulin sensitivity Research Validation: Clinical trials with 900+ participants confirmed selective fat metabolism effects with excellent safety profile The following guide provides detailed analysis of how AOD-9604 targets fat cells, from receptor binding to metabolic outcomes
HT has also been associated with viral triggers such as parvovirus, rubella, herpes simplex virus, EpsteinBarr virus, and human T-lymphotropic virus type 1
Analysis of EV miRNA cargo demonstrates over-representation of categories related to oxidative stress and miRNA functioning in categories related to both dopamine metabolism and nicotinic acetylcholine receptor signaling (Table 2)
